Green Jennifer B, Feinglos Mark N
Division of Endocrinology, Metabolism, and Nutrition, Duke University Medical Center, Baker House Room 280, Durham, NC 27710, USA.
Curr Diab Rep. 2007 Oct;7(5):369-75. doi: 10.1007/s11892-007-0060-0.
Diabetes mellitus and obesity have become increasingly prevalent problems worldwide. Unfortunately, with traditionally prescribed glucose-lowering medications most individuals with diagnosed diabetes do not achieve and maintain adequate glycemic control over time; it may be even more challenging to lower blood glucose to an appropriate level without inducing a significant associated weight gain. Exenatide and rimonabant are recently developed agents that have demonstrated benefit in both glucose lowering and reduction of body weight. These medications may well prove to be attractive alternatives or additions to our more established diabetes therapies; however, these drugs have a side-effect profile that may limit their applicability to certain populations.
糖尿病和肥胖症已成为全球日益普遍的问题。不幸的是,使用传统处方的降糖药物,大多数已确诊的糖尿病患者随着时间推移无法实现并维持足够的血糖控制;在不引起显著体重增加的情况下将血糖降至适当水平可能更具挑战性。艾塞那肽和利莫那班是最近开发的药物,已证明在降低血糖和减轻体重方面均有益处。这些药物很可能被证明是现有糖尿病治疗方法有吸引力的替代方案或补充;然而,这些药物的副作用可能会限制它们在某些人群中的适用性。